Merck: A Dividend Growth Stock Worth Considering

Summary:

  • Merck reported positive quarterly earnings with 6.7% year-over-year revenue growth and improved operating margin.
  • The company generated strong leveraged free cash flow and reduced financial leverage, improving its net debt position.
  • Merck has raised dividends for 12 consecutive years with an average growth rate nearing 10%.

Merck Research Facility South San Francisco

JasonDoiy

Overview

Merck (NYSE:MRK) is a global healthcare company with two main parts: Pharmaceuticals for human and Animal Health. In the Pharmaceutical section, they provide various human health products, including those for cancer, hospital care, auto immune-related issues, nervous system disorders, heart conditions, and diabetes. They also offer


Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in MRK over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


Leave a Reply

Your email address will not be published. Required fields are marked *